论文部分内容阅读
目的通过布地奈德(普米克令舒)联合万托林加压雾化吸入治疗新生儿呼吸窘迫综合征(NRDS)观察临床治疗效果。方法将符合标准的47例呼吸窘迫综合征患儿分为治疗组(31例)和对照组(16例)两组;治疗组在常规治疗的基础上,给予布地奈德联合万托林加压雾化吸入,用药24～72h对比观察两组患儿临床表现及血气变化情况。结果与对照组相比,治疗组24～72h临床症状及血气明显改善,治疗组优于对照组,差异有统计学意义(P<0.05)。结论布地奈德联合万托林加压雾化吸入治疗新生儿呼吸窘迫综合征疗效肯定,且操作方便,特别易于基层医院推广使用。
Objective To observe the clinical effect of Budesonide (Pulmicort Respubriform) combined with Vanthorid Atomized inhalation on neonatal respiratory distress syndrome (NRDS). Methods A total of 47 children with respiratory distress syndrome were divided into treatment group (31 cases) and control group (16 cases). The treatment group was given budesonide Athalation, medication 24 ~ 72h comparative observation of two groups of children with clinical manifestations and blood gas changes. Results Compared with the control group, the clinical symptoms and blood gas of the treatment group improved significantly from 24 to 72 hours, the treatment group was better than the control group, the difference was statistically significant (P <0.05). Conclusions Budesonide combined with Vanthorin inhalation for treatment of neonatal respiratory distress syndrome is effective and easy to operate, especially for primary hospitals.